Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest update is out from AIM Vaccine Co., Ltd. Class H ( (HK:6660) ).
AIM Vaccine Co., Ltd. has announced the submission of an application for clinical trials of its mRNA RSV vaccine to the U.S. FDA. Preclinical tests showed that the vaccine’s immune response was significantly higher than that of internationally marketed products. As RSV is a highly contagious respiratory infection with no approved antiviral drugs or vaccines, AIM Vaccine’s development could significantly impact the global market, which is projected to grow substantially by 2030. This advancement positions the company for accelerated internationalization and performance growth.
More about AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. is a leading enterprise in the development of mRNA vaccine products in China, with a mature research and development system for these vaccines. The company has established a sound quality management system and a commercial-scale production facility that meets GMP standards. AIM Vaccine Co., Ltd. is at the forefront of the mRNA vaccine technology platform and has secured an independent patent for this technology.
YTD Price Performance: -10.91%
Average Trading Volume: 3,441,289
Technical Sentiment Consensus Rating: Buy
For a thorough assessment of 6660 stock, go to TipRanks’ Stock Analysis page.
